Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2477-2480

  De Iuliis, Francesca ^a   Taglieri, Ludovica ^a   Amoroso, Lucrezia ^b   Vendittozzi, Stefania ^b   Blasi, Luciana ^b   Salerno, Gerardo ^a   Lanza, Rosina ^c   Scarpa, Susanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Departments of Radiology Oncology and Anatomo Pathology   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bisphosphonates; Bone metastasis; Osteonecrosis of the jaw; Zoledronic acid

Indexed keywords

CALCIUM; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

AGED; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DENTAL CARIES; DENTAL PROCEDURE; ENDODONTICS; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; PANORAMIC RADIOGRAPHY; PERIODONTAL DISEASE; PRACTICE GUIDELINE; RISK ASSESSMENT; SMOKING; SOLID TUMOR; TOOTH EXTRACTION; BONE TUMOR; FEMALE; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MOUTH DISEASE;

BISPHOSPHONATES; BONE METASTASIS; OSTEONECROSIS OF THE JAW; ZOLEDRONIC ACID;

AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIAGNOSIS, ORAL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED;

EID: 84902964899     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bundred N: Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 38: 776-786, 2012.
2. Hagiwara M, Delea TE, Cong Z and Chung K: Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer 22: 103-113, 2014.
3. Mehrotra B and Ruggero S: Bisphosphonate complications including osteonecrosis of the jaw. Hematology 1: 356-360, 2006.
4. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S and Tonini G: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003.
5. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Phamacol Exp Ther 302: 1055-1061, 2002.
6. Santini D, Vincenzi B, Tonini G, Scarpa S and Baldi A: Zoledronic acid exhibits inhibitory effects on osteoblstic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 3215, 2003.
7. Gnant M, Dubsky P and Hadji P: Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 192: 65-91, 2012.
8. Atanes-Bonome P, Atanes-Bonome A, Rios-Lage P and Atanes-Sandoval AD: Bisphosphonate-related osteonecrosis of the jaw. Semergen 13: 35-39, 2013.
9. Marx RE: Pamidronate-(Aredia) and zoledronate-(Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117, 2003.
10. Bagan J V, Murillo J, Jimenez Y, Poveda R, Millan MA, Sanchis JM, Silvestre FJ and Scully C: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34: 120-123, 2005.
11. Carter GD and Goss AN: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48: 268, 2003.
12. Durie BGM, Katz M and Crowley J: Osteonecrosis of the jaws in myeloma: time-dependent correlation with Aredia and Zometa use. Blood 104: 756, 2004.
13. Piccioli A: Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Eur J Orthop Surg Traumatol 14: 123-128, 2013.
14. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E and Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587, 2005.
15. Migliorati CA, Epstein JB, Abt E and Berenson JR: Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 7: 34-42, 2011.
16. Sardella A, Carrassi A, Tarozzi M and Lodi G: Bisphosphonate-related osteonecrosis of the jaws associated with photodynamic therapy. J Oral Maxillofac Surg 69: 314-316, 2011.
17. Badros A, Weikei D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, GahresN, sausville E, Ord R and Meiller T: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945-952, 2006.
18. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB and Shane E: Bisphosphonate-Associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 22: 1479-1491, 2007.
19. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twildw P and Anderson K: Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464-2247, 2007.
20. Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff PL, Canallatos P and Sullivan MA: Osteonecrosis of the jaw-prevention and treatment strategies for oral health professionals. Oral Oncol 49: 878-886, 2013.
21. Teah MJ, Syme SL, Scheper M and Weikel DS: The care and management of bisphosphonate-Associated osteonecrosis of the jaw in the patient with multiple myeloma: a case study. J Dent Hyg 87: 181-187, 2013.
22. Shannon J, Modelevsky S and Grippo AA: Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 59: 2350-2355, 2011.
23. Reid IR and Cornish J: Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8: 90-96, 2011.
24. Marx RE, Cillo JE Jr and Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 14: 2397-2410, 2007.
25. Sarin J, DeRossi SS and Akintoye SO: Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14: 277-285, 2008.
26. Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C, Beckmann MW, Fasching PA, Kreusch T, Mackensen A, Wullich B, Schett G and Spriewald BM: Major histocompatibility complex class II polymorphisms are associated with the development of antiresorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 14: 71-75, 2013
27. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D and Krimmel M: Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and riskfactors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112: 605-609, 2009.